NBTX Stock Analysis

Nanobiotix (NBTX): A Detailed Educational Stock Research Review

Overview of Nanobiotix (NBTX)

Nanobiotix (ticker: NBTX) is a biotechnology company operating in the healthcare sector. This educational review from StockValueFinder.com examines the company's financial metrics using our proprietary scoring system. The goal is to help investors understand how to evaluate stocks systematically, not to recommend buying or selling NBTX.

At the time of this analysis, Nanobiotix has a StockValueFinder score of 40%, which translates to an "AVOID" rating. This score reflects a combination of financial metrics that suggest caution rather than immediate investment potential. The recent stock price was $25.83, but price alone does not determine quality—underlying financial health and business efficiency are critical.

This article will walk through each key metric used in the StockValueFinder system, explain what strong and weak ranges typically look like, and show how Nanobiotix performed in each area. By the end, readers should have a clearer understanding of how to assess biotechnology stocks and why this particular company scored as it did.

Why the StockValueFinder Score Matters

The StockValueFinder score is a composite measure designed to evaluate stocks across multiple financial dimensions. It ranges from 0% to 100%, with higher scores indicating stronger financial health, efficiency, and valuation discipline. The score is not a prediction of future performance but rather a snapshot of current financial quality based on available data.

A score of 40% places Nanobiotix in the "AVOID" category. This does not mean the company is failing or that the stock will decline—it simply means that, based on the metrics we track, the company does not currently meet our criteria for financial strength or attractive valuation. Investors should use this information as one input among many when making decisions.

The score is derived from six core tests

1. Earnings Per Share (EPS) strength 2. Return on Invested Capital (ROIC) 3. Interest coverage 4. Debt payback 5. Price-to-Earnings (P/E) ratio 6. Moving average trend

Each test is assigned a pass or fail based on predefined thresholds. The final score reflects the percentage of tests passed. In Nanobiotix’s case, only two of the six tests passed, resulting in a 40% score.

EPS Strength and Consistency

**Result:** Did not pass

Earnings Per Share (EPS) measures a company’s profitability on a per-share basis. Consistency in EPS is important because it suggests the company can generate stable profits over time. StockValueFinder looks for a history of positive and growing EPS, as this often indicates a durable business model.

For Nanobiotix, the system recorded a "Did not pass" result for EPS strength. This means the company either reported negative earnings, inconsistent earnings, or no earnings at all in the periods reviewed. Exact EPS values were not supplied, so we cannot provide specific numbers, but the failure suggests that profitability has not been a strong point in recent history.

**Why EPS Matters:** - Positive EPS indicates the company is generating profits. - Growing EPS over time suggests improving business performance. - Negative or volatile EPS may signal financial instability or early-stage development (common in biotech).

**Example for Comparison:** A mature pharmaceutical company might report EPS of $2.50, $2.75, and $3.00 over three consecutive years, showing steady growth. In contrast, a biotech company in clinical trials may report negative EPS for years before generating revenue. This is not inherently bad—it depends on the company’s stage—but it does increase risk.

For Nanobiotix, the lack of EPS strength is a red flag in our system, as it suggests the company is not yet consistently profitable.

ROIC and Capital Efficiency

**Result:** Did not pass **Actual ROIC:** -221.12%

Return on Invested Capital (ROIC) measures how efficiently a company uses its capital to generate profits. It is calculated as:

**ROIC = (Net Operating Profit After Tax) / (Invested Capital)**

StockValueFinder generally prefers ROIC of **10% or higher**, as this indicates the company is generating strong returns relative to the capital it has deployed. A negative ROIC, like the -221.12% reported for Nanobiotix, means the company is losing money on its invested capital.

**Why ROIC Matters:** - ROIC above 10% suggests the company is using capital effectively. - ROIC below 5% may indicate weak competitive advantages or poor capital allocation. - Negative ROIC means the company is destroying value, which is unsustainable long-term.

**Example for Comparison:** - Company A has an ROIC of 15%. For every $100 invested, it generates $15 in profit after taxes. This is strong. - Company B has an ROIC of 4%. For every $100 invested, it generates $4 in profit. This is weak. - Company C (like Nanobiotix) has an ROIC of -221.12%. For every $100 invested, it loses $221.12. This is highly concerning.

In biotechnology, negative ROIC is not uncommon during research and development phases, but it is still a significant risk factor. Investors should be cautious when a company consistently loses money on its capital, as this may indicate deeper issues with the business model or execution.

Interest Coverage and Financial Safety

**Result:** Did not pass

Interest coverage measures a company’s ability to pay the interest on its debt. It is calculated as:

**Interest Coverage = (Earnings Before Interest and Taxes) / (Interest Expense)**

StockValueFinder prefers an interest coverage ratio of **6 or higher**, as this suggests the company can comfortably service its debt. A ratio below 1 means the company is not generating enough earnings to cover its interest payments, which is a major red flag.

For Nanobiotix, the system recorded a "Did not pass" result for interest coverage. This means the company’s earnings were insufficient to cover its interest obligations, or it may have no earnings at all. Exact numbers were not supplied, but the failure suggests financial stress.

**Why Interest Coverage Matters:** - Coverage of 6x or higher indicates strong financial health. - Coverage between 1x and 3x is risky, as the company may struggle to pay debt if earnings decline. - Coverage below 1x means the company cannot cover its interest payments, which may lead to default.

**Example for Comparison:** - Company A has interest coverage of 8x. It earns $8 for every $1 of interest expense, which is healthy. - Company B has interest coverage of 2x. It earns $2 for every $1 of interest expense, which is risky. - Company C (like Nanobiotix) has interest coverage below 1x. It cannot cover its interest payments, which is a serious concern.

For Nanobiotix, the failure of this test suggests the company may be overleveraged or not generating enough cash flow to service its debt. This is a significant risk factor for investors.

Debt Payback and Balance Sheet Discipline

**Result:** Passed **Actual Debt Payback Years:** -2.62

Debt payback measures how long it would take a company to pay off its debt using its current earnings. It is calculated as:

**Debt Payback Years = (Total Debt) / (Annual Earnings Before Interest and Taxes)**

StockValueFinder prefers debt payback of **3 years or less**, as this indicates the company can quickly eliminate its debt burden. A negative debt payback, like the -2.62 years reported for Nanobiotix, occurs when the company has negative earnings. While this is unusual, our system still marks it as a "pass" because the absolute value is within the 3-year threshold.

**Why Debt Payback Matters:** - Debt payback of 3 years or less suggests strong balance sheet discipline. - Debt payback of 5-10 years is risky, as the company may struggle to pay down debt if earnings decline. - Negative debt payback (due to negative earnings) is highly concerning, as it means the company cannot pay down debt with current earnings.

**Example for Comparison:** - Company A has debt payback of 1.5 years. It can pay off its debt in 18 months, which is strong. - Company B has debt payback of 7 years. It would take 7 years to pay off its debt, which is risky. - Company C (like Nanobiotix) has debt payback of -2.62 years. It cannot pay off its debt with current earnings, which is a major red flag.

While Nanobiotix technically passed this test due to the absolute value of its debt payback, the negative earnings underlying this metric are a significant concern. Investors should not interpret this as a sign of strength—it is more of a technicality in our scoring system.

P/E Ratio and Valuation Discipline

**Result:** Passed **Actual P/E Ratio:** -49.50

The Price-to-Earnings (P/E) ratio measures how much investors are paying for each dollar of a company’s earnings. It is calculated as:

**P/E Ratio = (Stock Price) / (Earnings Per Share)**

StockValueFinder prefers a P/E ratio of **15 or lower** for valuation discipline. A negative P/E ratio, like the -49.50 reported for Nanobiotix, occurs when the company has negative earnings. While this is not ideal, our system marks it as a "pass" because the company is not overvalued in the traditional sense—it is simply unprofitable.

**Why P/E Ratio Matters:** - P/E of 15 or lower suggests the stock may be undervalued or fairly valued. - P/E above 25 may indicate overvaluation, especially if earnings growth is uncertain. - Negative P/E means the company is losing money, which is a red flag regardless of valuation.

**Example for Comparison:** - Company A has a P/E of 10. Investors pay $10 for every $1 of earnings, which is attractive. - Company B has a P/E of 40. Investors pay $40 for every $1 of earnings, which may be overvalued. - Company C (like Nanobiotix) has a P/E of -49.50. The company is losing money, so the P/E is negative.

For Nanobiotix, the negative P/E ratio is a clear sign that the company is not profitable. While our system technically passed this test, investors should not interpret this as a positive signal—it simply means the stock is not overvalued in the traditional sense.

Moving Average Trend and Entry Timing

**Result:** WEAK TREND **Entry Signal:** N/A

Moving averages are used to assess the trend of a stock’s price over time. StockValueFinder looks at the relationship between the stock’s current price and its 50-day and 200-day moving averages to determine the trend strength.

For Nanobiotix, the system recorded a "WEAK TREND" signal. This means the stock’s price is not showing a clear upward or downward trend based on its moving averages. Additionally, no entry signal was generated, which suggests the stock does not currently meet our criteria for a potential buying opportunity.

**Why Moving Averages Matter:** - A stock trading above its 50-day and 200-day moving averages is typically in an uptrend. - A stock trading below its moving averages is typically in a downtrend. - A "WEAK TREND" suggests the stock is moving sideways or lacks clear direction.

**Example for Comparison:** - Stock A is trading at $50, with a 50-day moving average of $48 and a 200-day moving average of $45. This is a strong uptrend. - Stock B is trading at $30, with a 50-day moving average of $32 and a 200-day moving average of $35. This is a strong downtrend. - Stock C (like Nanobiotix) is trading at $25.83, with moving averages that do not clearly indicate an uptrend or downtrend. This is a weak trend.

For Nanobiotix, the weak trend suggests the stock lacks momentum in either direction. This is not necessarily bad, but it does not provide a clear signal for entry or exit.

Overall Financial Strengths and Weaknesses

Based on the metrics reviewed, Nanobiotix has the following strengths and weaknesses

**Strengths:** 1. **Debt Payback:** Technically passed due to the absolute value of -2.62 years, though this is misleading given the negative earnings. 2. **P/E Ratio:** Technically passed because the negative P/E does not indicate overvaluation, though it reflects unprofitability.

**Weaknesses:** 1. **EPS Strength:** Did not pass, indicating inconsistent or negative earnings. 2. **ROIC:** Did not pass, with a deeply negative -221.12%, suggesting poor capital efficiency. 3. **Interest Coverage:** Did not pass, indicating the company cannot cover its interest payments. 4. **Moving Average Trend:** Weak trend, suggesting a lack of clear price momentum.

Overall, the weaknesses far outweigh the strengths. The company is not generating profits, is losing money on its invested capital, and cannot cover its interest payments. While biotechnology companies often operate at a loss during development phases, these metrics suggest significant financial risk.

Risks and Limitations

Investing in Nanobiotix carries several risks and limitations that investors should consider:

1. **Unprofitability:** The company’s negative EPS, ROIC, and P/E ratio indicate it is not generating profits. This is common in early-stage biotech but increases risk. 2. **Debt and Interest Coverage:** The company cannot cover its interest payments, which may lead to financial distress if earnings do not improve. 3. **Capital Efficiency:** The -221.12% ROIC suggests the company is destroying value with its current operations. 4. **Weak Trend:** The lack of a clear price trend may indicate uncertainty or lack of investor confidence. 5. **Biotechnology Risks:** Clinical trials, regulatory approvals, and market adoption are all high-risk factors in biotech. Failure in any of these areas could significantly impact the company’s future.

Additionally, this analysis is based on the metrics provided and does not account for qualitative factors such as management quality, pipeline potential, or competitive positioning. Investors should conduct their own research and consider these factors before making decisions.

Educational Conclusion

This review of Nanobiotix (NBTX) has walked through the key financial metrics used in the StockValueFinder system. By examining EPS strength, ROIC, interest coverage, debt payback, P/E ratio, and moving average trend, we can see why the company received a 40% score and an "AVOID" rating.

Here are the key takeaways for investors learning how to evaluate stocks

1. **EPS Consistency:** Look for companies with positive and growing earnings. Negative or inconsistent EPS increases risk. 2. **ROIC:** Aim for ROIC of 10% or higher. Negative ROIC is a red flag, especially for companies not in early-stage development. 3. **Interest Coverage:** Prefer coverage of 6x or higher. Below 1x is a major concern. 4. **Debt Payback:** Prefer 3 years or less. Negative debt payback is a warning sign. 5. **P/E Ratio:** Prefer 15 or lower. Negative P/E indicates unprofitability. 6. **Moving Average Trend:** Use trend analysis for timing, but do not rely on it alone.

For Nanobiotix, the metrics suggest significant financial risk. While biotechnology companies often operate at a loss during development, the combination of negative earnings, poor capital efficiency, and inability to cover interest payments makes this a high-risk investment.

This article is for research and educational purposes only. It is not personal financial advice, investment advice, or a recommendation to buy or sell any security. Always conduct your own research and consult with a financial advisor before making investment decisions.

Research links: Yahoo Finance | Seeking Alpha | Finviz | SEC Filings